Artelo Biosciences (ARTL) director awarded 292 stock options at $1.71

Rhea-AI Filing Summary

Artelo Biosciences, Inc. director Blayney Douglas received an award of stock options covering 292 shares of common stock at an exercise price of $1.71 per share. The options expire on January 30, 2036 and are held directly.

According to the grant terms, all 292 option shares vest in full if Douglas continues as a service provider until the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026 or the day before the next annual stockholder meeting following that date. After this grant, he beneficially owns 292 derivative securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blayney Douglas

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.71	01/30/2026		A		292		(1)	01/30/2036	Common Stock	292	$0.00	292	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artelo Biosciences (ARTL) report for Blayney Douglas?

Artelo Biosciences reported that director Blayney Douglas received stock options covering 292 shares of common stock. The options were awarded on January 30, 2026, and represent derivative securities he now beneficially owns directly, according to the disclosure details.

What are the key terms of Blayney Douglas’s Artelo Biosciences stock option grant?

Blayney Douglas received stock options to purchase 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share. These options expire on January 30, 2036, providing a long-dated right to buy shares at that stated price.

How and when do Blayney Douglas’s Artelo (ARTL) options vest?

The 292 stock option shares vest 100% if Blayney Douglas continues as a service provider. Vesting occurs on the earlier of one year after the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date.

What does the Form 4 show about Blayney Douglas’s ownership in Artelo Biosciences?

The disclosure shows Blayney Douglas beneficially owns 292 derivative securities in the form of stock options. These options are reported as directly held, reflecting his right to acquire Artelo Biosciences common stock under the specified exercise and vesting terms.

What type of security did Blayney Douglas receive from Artelo Biosciences (ARTL)?

Blayney Douglas received “Stock Options (right to buy)” Artelo Biosciences common stock. Each option relates to one underlying share, for a total of 292 shares, with an exercise price of $1.71 and an expiration date of January 30, 2036.